Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01090492 · ClinicalTrials.gov registry record · Phase 2
PF-00489791 For The Treatment Of Raynaud's
A Phase 2 study of Peripheral Vascular Disease and Raynaud's Disease, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 243
- Enrollment target
- 20
- Study locations
NCT01090492: Completed Phase 2 study of Peripheral Vascular Disease and Raynaud's Disease, sponsored by Pfizer.
NCT01090492 is a Phase 2 study of Peripheral Vascular Disease and Raynaud's Disease that has completed, run by Pfizer. The registered enrollment target is 243 participants, below the 273-participant average among 25 other Peripheral Vascular Disease trials with a reported enrollment target (11% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01090492, a Phase 2 study of Peripheral Vascular Disease and Raynaud's Disease, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 243 participants
- Enrollment target
- 20
- Study locations
Study Summary
The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.
Primary Outcome
The Raynaud's Condition score (RCS) is participant's rating of difficulty considering number of attacks, duration, amount of pain, numbness, or other symptoms caused in the fingers (including painful sores) due to the Raynaud's phenomenon every day and impact of Raynaud's alone on use of hands every day. An 11 point Likert scale is used to rate the difficulty caused by the condition each day with 0 = no difficulty and 10 = extreme difficulty. Participants were asked to select the number that bes
Conditions Studied
Interventions
- DRUG PF-00489791
Study Locations (20)
Michigan
- University of Michigan - Ann Arbor
- University of Michigan Health System - Ann Arbor
- West Michigan Rheumatology, PLLC - Grand Rapids
New York
- The Center for Rheumatology - Albany
- Regional Rheumatology Associates - Binghamton
- AAIR Research Center - Rochester
Indiana
- Diagnostic Rheumatology and Research, PC - Indianapolis
- Memorial Health System, Inc. dba Memorial Medical Group Clinical Research Institute - South Bend
Maryland
- Johns Hopkins University - Division of Rheumatology - Baltimore
- The Center for Rheumatology and Bone Research - Wheaton
Pennsylvania
- East Penn Rheumatology Associates, PC - Bethlehem
- Altoona Center for Clinical Research - Duncansville
California
- Stanford Hospital and Outpatient Center - Redwood City
Connecticut
- University of Connecticut Health Center - Farmington
District of Columbia
- Georgetown University Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2010-08-04 |
| Est. Completion | 2011-05-31 |
| Phase | Phase 2 |
What the finished NCT01090492 record still lists
NCT01090492 is an interventional study that assigns participants to a tested intervention. The registered 243 participants enrollment target is mid-sized for trials with a published cap, below the 273-participant average among 25 other Peripheral Vascular Disease trials with a reported enrollment target (11% lower).
The record links to 2 conditions, with Peripheral Vascular Disease appearing as the primary indexed condition, and to 1 intervention - of which PF-00489791 is the first listed.
NCT01090492 names 20 study sites across 13 states, led by Michigan, New York, Indiana.
Frequently Asked Questions
What is clinical trial NCT01090492 about?
NCT01090492 is a clinical study titled "PF-00489791 For The Treatment Of Raynaud's". The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.
What is the current status of trial NCT01090492?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 243 participants. The study started on 2010-08-04. Estimated completion is 2011-05-31.
What conditions does trial NCT01090492 study?
This clinical trial studies the following conditions: Peripheral Vascular Disease, Raynaud's Disease.
What interventions are being tested in trial NCT01090492?
The interventions under investigation include: PF-00489791 (DRUG).
Who is sponsoring clinical trial NCT01090492?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01090492 being conducted?
This trial has 20 study locations across California, Connecticut, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Vascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01090492's enrollment target sits among peer trials
243 9th of 25 higher than 17 of 25 other Peripheral Vascular Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Vascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication
COMPLETED · Phase 2
-
Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease
COMPLETED · Phase 2
-
Improving Mobility After Revascularization in Peripheral Artery Disease
RECRUITING · Phase 3
-
Far Red Light to Improve Functioning in PAD
RECRUITING · NA
-
Leg Exercise Assistive Paddling (LEAP) Therapy for Peripheral Artery Disease
RECRUITING · NA
-
ENhancing Exercise with LIGHT to Improve Functioning in PAD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06253871 · 243 participants · Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
- NCT06289491 · 243 participants · NA
A Trial of Hydrus Microstent Versus Goniotomy
- NCT06536296 · 243 participants · NA
The Impact of Music Medicine on Preterm Brain Development and Behavior
- NCT06907615 · 243 participants · Phase 2
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI